Detalhe da pesquisa
1.
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
J Infect Dis
; 227(1): 71-82, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259542
2.
Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
Int J Infect Dis
; 41: 65-72, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26585940